Table 2. Comparison of ratios in concomitant drugs used at baseline and end‐point between non‐pioglitazone (control) and pioglitazone groups.
| Drug treatment | Baseline | P‐value | End‐point | P‐value | ||
|---|---|---|---|---|---|---|
| Control (%) | Pioglitazone (%) | Control (%) | Piolglitazone (%) | |||
| Insulin | 26/26 (100) | 22/22 (100) | 1 | 26/26 (100) | 22/22 (100) | 1 |
| Metformin | 16/26 (62) | 14/22 (64) | 0.88 | 16/26 (62) | 12/22 (55) | 0.62 |
| α‐Glucosidase inhibitor | 8/26 (31) | 6/22 (27) | 0.79 | 12/26 (46) | 6/22 (27) | 0.18 |
| Sulfonylureas | 0/26 (0) | 2/22 (9) | 0.12 | 3/26 (12) | 4/22 (18) | 0.52 |
| Calcium‐channel blockers | 10/26 (38) | 4/22 (18) | 0.12 | 14/26 (54) | 6/22 (27) | 0.06 |
| ACE‐I/ARB | 12/26 (46) | 7/22 (32) | 0.31 | 18/26 (69) | 11/22 (50) | 0.18 |
| Statins | 7/26 (27) | 10/22 (45) | 0.18 | 12/26 (46) | 15/22 (68) | 0.66 |
| Fibrates | 2/26 (8) | 1/22 (5) | 0.65 | 3/26 (12) | 2/22 (10) | 0.78 |
| Antiplatelet medications | 8/26 (31) | 2/22 (9) | 0.65 | 13/26 (50) | 4/22 (18) | 0.02 |